Clinical Trials

Clinical Trials

If you are interested in participating in our research, give us a call at (503)-207-2066 to determine your eligibility.

 

Current Clinical Research Projects at our Clinic

 

TauRx Therapeutics Ltd. (LUCIDITY) 

Protocol: TRx-237-039

Patients: <90 years old

Diagnostic: MCI/Early Alzheimer’s disease

Agent: Leuco-methylthioninium bis(hydromethanesulfonate) (LMTM)

Daily Oral Administration

Currently Enrolling: No

Lucidity Website

 

Athira Pharma Inc. (Act AD) 

Protocol: ATH-1017-AD-0202

Patients: 55-85 years old

Diagnostic: Probable Mild-Moderate AD

Agent: ATH-1017

Daily Subcutaneous Injection

Currently Enrolling: Closing Soon

Act AD Website

 

Athira Pharma Inc. (Lift AD) 

Protocol: ATH-1017-AD-0201

Patients: 55-85 years old

Diagnostic: Probable Mild-Moderate AD

Agent: ATH-1017

Daily Subcutaneous Injection

Currently Enrolling: No

Lift AD Website

 

Eli Lilly and Company (TRAILBLAZER-ALZ2)

Protocol: I5T-MC-AACI

Patients: 60-85 years old

Diagnostic: Prodromal AD or Mild AD Dementia

Agent: Donanemab

Intravenous Administration Every 4 Weeks

Currently Enrolling: Closing Soon

TRAILBLAZER-ALZ2 Website

 

Eli Lilly and Company (TRAILBLAZER-ALZ3)

Protocol: I5T-MC-AACM

Patients: 55-80 years old

Diagnostic: Prodromal AD or Mild AD Dementia

Agent: Donanemab

Intravenous Administration Every 4 Weeks

Currently Enrolling: Awaiting Activation to Begin Enrolling

Website Not Yet Provided

 

Alzheon Inc. (APOLLOE4)

Protocol: ALZ-801-AD301

Patients: 50-80 years old

Diagnostic: Early Alzheimer’s disease

Agent: ALZ-801

Twice Daily Oral Administration

Currently Enrolling: Yes

ALZ-801 Website

 

Alector Inc. (INVOKE-2)

Protocol: AL002-2

Patients: 50-85 years old

Diagnostic: Early Alzheimer’s disease

Agent: AL002

Intravenous Administration Every 4 Weeks

Currently Enrolling: Awaiting Activation to Begin Enrolling

AL002 Website

 

Novo Nordisk (EVOKE Plus)

Study ID: NN6535-4725

Patients: 55-85 years old

Diagnostic: Early Alzheimer’s disease

Agent: Semaglutide

Once Daily Oral Administration

Currently Enrolling: Awaiting Activation to Begin Enrolling

EVOKE Plus Website

 

Novo Nordisk (EVOKE)

Study ID: NN6535-4730

Patients: 55-85 years old

Diagnostic: Early Alzheimer’s disease

Agent: Semaglutide

Once Daily Oral Administration

Currently Enrolling: Awaiting Activation to Begin Enrolling

EVOKE Website

 

Biogen (ICARE AD)
Protocol: US-ALZ-11855
Patients: 18 or Older
Diagnostic: AD
Agent: Aducanumab

Intravenous Administration Every 4 Weeks
Currently Enrolling: Awaiting Activation to Begin Enrolling

Website Not Yet Provided

 

American College of Radiology (New IDEAS)
Study Name: Imaging Dementia-Evidence for Amyloid Scanning Study
Patients: Medicare Beneficiary with Medicare as Primary Insurance
Diagnostic: MCI or Dementia
Study Procedure: PET Scan with Pre- and Post-Scan Clinical Assessments
Currently Enrolling: Awaiting Activation to Begin Enrolling

New IDEAS Website

 

Eisai (Clarity AD)
Protocol: BAN2401-G000-301
Patients: 50-90 years old
Diagnostic: MCI due to AD/Mild AD
Agent: Monoclonal anti-amyloid antibody
Infusion
Currently Enrolling: No

Clarity AD Website